Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Affiliations

• ¹ Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany. h.salwender@asklepios.com.
• ² Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany.
• ³ Department of Hematology, Celltherapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
• ⁴ Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
• ⁵ Klinikum Chemnitz, Chemnitz, Germany.
• ⁶ Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
• ⁷ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
• ⁸ Charité Universitätsmedizin, Berlin, Germany.
• ⁹ University Hospital Cologne, Cologne, Germany.
• ¹⁰ Vrije Universiteit Brussel (VUB), Laboratory of Hematology and Immunology & Labor für Myelomforschung, Jette, Belgium.
• ¹¹ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
• ¹² Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
• ¹³ University Hospital Tubingen, Tubingen, Germany.
• ¹⁴ University Medical Center Mainz, Mainz, Germany.
• ¹⁵ University Hospital Bonn, Bonn, Germany.
• ¹⁶ Helios Hospital Berlin Buch, Buch, Germany.
• ¹⁷ Kath. Krankenhaus Hagen, Hagen, Germany.
• ¹⁸ University Hospital Hamburg, Hamburg, Germany.
• ¹⁹ University Hospital Essen, Essen, Germany.